22nd Century Group Announces Initial Results of Smoking Cessation Trial. 22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company’s Phase II-B clinical trial.
Visit the news at
www.businesswire.com/news/home/20111226005048/en/22nd-Century-Group-Announces-Initial-Results-Smoking
No comments:
Post a Comment